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Purpose: To evaluate the comparative therapeutic efficacy of radiofrequency ablation (RFA) and hepatic resection for the 
treatment of colorectal liver metastasis (CRLM). Methods: Between 1996 and 2008, 177 patients underwent RFA, 278 under-
went hepatic resection and 27 underwent combination therapy for CRLM. Comparative analysis of clinical outcomes was 
performed including number of liver metastases, tumor size, and time of CRLM. Results: Based on multivariate analysis, 
overall survival (OS) correlated with the number of liver metastases and the use of combined chemotherapy (P ＜  0.001, re-
spectively). Disease-free survival (DFS) also correlated with the number of liver metastases (P ＜  0.001). In the 226 patients 
with solitary CRLM ＜  3 cm, OS and DFS rates did not differ between the RFA group and the resection group (P = 0.962 and 
P = 0.980). In the 70 patients with solitary CRLM ≥  3 cm, DFS was significantly lower in the RFA group as compared with the 
resection group (P = 0.015). Conclusion: The results indicate that RFA may be a safe alternative treatment for solitary CRLM 
less than 3 cm, with outcomes equivalent to those achieved with hepatic resection. A randomized controlled study compar-
ing RFA and resection for patients with single small metastasis would help to determine the most efficient treatment modal-
ities for CRLM.
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INTRODUCTION
Surgical resection is viewed as the gold standard of 
treatment for resectable liver metastasis from colorectal 
cancer (CRLM) [1,2]. Several groups have reported 5-year 
survival rates in the range of 23 to 71% for surgical re-
section [3,4]. However, only 10 to 20% of patients with 
CRLM are candidates for surgical resection; the majority 
are not suitable for resection because of anatomically 
ill-located lesions, functional insufficiency of hepatic re-
serves, medical comorbidities and extra-hepatic meta-
stasis [5]. Radiofrequency ablation (RFA) is an alternative 
therapy for CRLM when hepatic resection cannot be 
performed. RFA has the advantage of being minimally in-
vasive and is a relatively low-risk procedure for the treat-
ment of focal liver tumors, especially in comparison with 
open surgical resection [6]. On the other hand, RFA carries 
its own associated morbidity and mortality rates in both 
immediate post-procedure and over the long term [7]. 
Furthermore, there are unresolved technical limitations Kyung Ho Kim, et al.
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associated with RFA, such as heat sink effects on nearby 
blood vessels and local tissue destruction [8]. Local re-
currence remains one of the greatest disadvantages of RFA 
for the treatment of hepatic tumors [9]. There are conflict-
ing reports in the literature on the comparative efficacy of 
RFA and hepatic resection. Some results support a pro-
spective clinical trial comparing RFA and resection, while 
other reports indicate that RFA is inferior to surgical re-
section [4,10,11]. Although surgery is still the recom-
mended treatment modality for patients with CRLM, the 
majority of these patients are not surgical candidates [12]. 
There are few reports in the literature of randomized con-
trolled trials comparing RFA and resection for CRLM, and 
analysis of comparative outcomes between RFA and re-
section has yielded somewhat inconsistent results. Thus, 
the exact role and long-term outcomes associated with 
RFA for CRLM are unclear. The purpose of the current 
study was to evaluate the comparative therapeutic effi-
cacy of RFA and hepatic resection for CRLM.
METHODS
Eligibility and enrollment
Between January 1996 and August 2008, 505 patients 
with CRLM underwent RFA, hepatic resection or a combi-
nation of RFA and resection at Asan Medical Center. All pa-
tients had liver metastasis with diagnoses by computed to-
mography (CT), magnetic resonance imaging (MRI), posi-
tron emission tomography (PET), ultrasonography or 
biopsy. Patients with extrahepatic metastasis were ex-
cluded when treatment of CRLM was performed. Of the 
301 patients who underwent hepatic resection, 23 patients 
with positive resection margin were also excluded. Of the 
482 patients included in the study, 177 were treated by RFA, 
278 by curative surgical resection, and 27 by combination 
therapy. Synchronous colorectal cancer and liver meta-
stases were identified in 258 (53.5%) patients and meta-
chronous liver metastases were detected in 224 (46.5%) of 
the 482 patients. RFA was performed in cases of sur-
gery-prohibitive comorbidities such as severe car-
diovascular or pulmonary disease, difficult anatomical site 
for surgical resection, and more than four hepatic meta-
stases over the entire liver [13,14]. A total of 44 (24.9%) of 
the 177 patients presented with comorbid diseases (13 cas-
es of chronic obstructive pulmonary disease, 4 cases of 
chronic renal failure, 10 cases of liver cirrhosis, 2 trans-
plantations and 15 cases of heart failure), and the position 
of the hepatic lesion was located in an anatomic site diffi-
cult for resection, such as the center of the liver, in 38 
(21.5%) of the 177 patients. Otherwise, all patients with 
CRLM were initially considered for resection. All patients 
were recruited prospectively. The endpoints were re-
currence, disease-free survival (DFS) and overall survival 
(OS). The study was conducted with the approval of the 
Institutional Review Board for Human Research (Asan 
Clinical Research Center, Seoul, Korea) in accordance with 
the Helsinki Declaration.
Treatments and follow-up
RFA was performed intraoperatively under general an-
esthesia or percutaneously under local anesthesia using 
ultrasonographic guidance to ensure that at least a 1-cm 
ablation margin was achieved around the tumor. Single or 
triple-cluster, 17 gauge (4.5 Fr), internally cooled electro-
des (Valleylab, Boulder, CO, USA) were used. A single 
electrode with a 3-cm exposed tip was used for small tu-
mors; a triple-cluster electrode with a 2.5-cm exposed tip 
for large tumors was used at the discretion of the 
radiologist. Radiofrequency current was emitted for 10 to 
15 minutes with the generator set to deliver the maximum 
power in impedance control mode. Destruction of the liver 
metastasis was confirmed by follow-up CT and ultra-
sonography the next day. 
Synchronous hepatic resection by primary operation 
was performed on 214 patients (77.0%) and metachronous 
resection was done on 64 (23.0%) of the 278 patients in the 
resection group. Fourteen patients underwent lobectomy, 
42 patients segmentectomy, and 222 patients subseg-
mentectomy. The surgical resection margin was 0.7 ± 0.8 
cm (range, 0.1 to 7.0 cm). During laparotomy, intra-
operative ultrasonography of the liver was routinely per-
formed to detect metastatic tumors and to evaluate their 
anatomical location and resectability. In the RFA group, 
164 (92.7%) of the 177 patients underwent post-treatment 
chemotherapy; 247 (88.8%) of the 278 patients in the re-RFA and resection for colorectal liver meta
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Table 1. Patient clinicopathological characteristics
Variable
RFA 
(n = 177)
Resection 
(n = 278)
P-value
a) Resection ＋  RFA 
(n = 27)
P-value
b)
Age (yr) 60.4 ± 10.7 57.1 ± 10.9 0.001 55.7 ± 11.1 0.013
Sex
Male 121 (68.4) 168 (60.4) 0.091 15 (55.6) 0.178
Female 56 (31.6) 110 (39.6) 12 (44.4)
Synchronicity
Synchronous metastasis 17 (9.6) 214 (77.0) ＜0.001 27 (100) ＜0.001
Metachronous metastasis 160 (90.4) 64 (23.0) 0 (0)
No. of liver metastasis
Mean 1.6 ± 0.9 1.5 ± 0.8 0.162 3.1 ± 1.6 ＜0.001
Single 113 (63.8) 183 (65.8) 0.546 0 (0) ＜0.001
Multiple 64 (36.2) 95 (34.2) 27 (100)
Maximum tumor size 
Mean (cm) 2.1 ± 1.0 2.6 ± 2.0 0.004 2.1 ± 1.4 0.010
＜3 cm 145 (81.9) 182 (65.5) ＜0.001 21 (77.8) 0.001
≥3 cm 32 (18.1) 96 (34.5) 6 (22.2)
Location of liver metastasis
Unilobar 148 (83.6) 224 (80.6) 0.456 12 (44.4) ＜0.001
Bilobar 29 (16.4) 54 (19.4) 15 (55.6)
Chemotherapy after treatment
No 13 (7.2) 31 (11.2) 0.197 0 (0) 0.092
Yes 164 (92.7) 247 (88.8) 27 (100)
Hospital admission (day) 4.2 ± 2.8 13.4 ± 4.5 ＜0.001 15.0 ± 14.7   ＜0.001
Morbidity 11 (6.2) 59 (21.2) ＜0.001 10 (37.0) ＜0.001
Bleeding (transfusion)       2       13       3
Abscess       8       17       3
Wound infection       0       10       3
Transient respiratory failure       1        8       1
Ileus       0       11       0
Values are presented as mean ± SD or number (%).
RFA, radiofrequency ablation.
a)RFA vs. resection. 
b)RFA vs. resection vs. resection ＋  RFA.
section group and all 27 patients (100%) in the combina-
tion therapy group underwent post-treatment che-
motherapy.
Follow-up was carried out postoperatively every 3 to 6 
months. The evaluation included clinical examination, 
common blood chemistry, serum CEA, abdomen/chest 
CT, and specific procedures such as MRI, PET and bone 
scan when indicated.
Statistical analysis
Clinicopathologic continuous variables among the 
groups were compared using Student’s t-test, Kruskal 
Wallis test or one-way analysis of variance with least sig-
nificant difference multiple comparison. Categorical vari-
ables were compared by cross table analysis using the χ
2 
test or Fisher exact test and potential variables were veri-
fied by multivariate analysis using binary logistic 
regression. OS and DFS were compared using the 
Kaplan-Meier method with log-rank test, and survival fac-
tors were verified using a Cox proportional hazard re-
gression model. The significance level was set at 5% for 
each analysis, and all calculations were performed using 
SPSS ver. 18 (SPSS Inc., Chicago, IL, USA). 
RESULTS
Clinical characteristics of the patients
The clinical characteristics of the 482 patients included 
in the analysis are summarized in Table 1 (RFA, 177 pa-Kyung Ho Kim, et al.
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Fig. 1. Examples of radiologic images 
indicating that radiofrequency abla-
tion (RFA) was recommended in the 
current study. (A) Anatomic sites 
difficult for resection (left image, 
pre-RFA; right image, post-RFA). (B) 
Multiple lesions treated with com-
bination therapy (left images, pre- 
treatment; right images, post-treat-
ment).
tients; resection, 278 patients; combination therapy, 27 pa-
tients). Examples of radiologic findings indicating that 
RFA was recommended in the current study are pre-
sented in Fig. 1. The RFA group had more patients with 
metachronous liver metastasis whereas the resection 
group had more patients with synchronous liver 
metastasis. All patients in the combination therapy group 
had synchronous liver metastasis. Both the RFA and re-
section groups had more patients with single metastasis; 
all patients in the combination therapy group had multi-
ple metastases. The mean number of liver metastases was 
1.6 (range, 1 to 5) in the RFA group, 1.5 (range, 1 to 6) in the 
resection group and 3.1 (range, 2 to 8) in the combination 
therapy group. The mean maximum tumor diameter was 
2.1 cm (range, 0.5 to 6.2 cm) in the RFA group, 2.6 cm 
(range, 0.5 to 13.0 cm) in the resection group and 2.1 cm 
(range, 0.5 to 6.0 cm) in the combination therapy group. 
Unilobar metastases were observed in 148 (83.6%) of 177 
patients in the RFA group, 224 (80.6%) of 278 patients in 
the resection group and 12 (44.4%) of 27 patients in the 
combination therapy group. There were no significant 
differences in the frequency of chemotherapy among the 
groups (P = 0.092). The mean hospitalization period was 
4.2 days (range, 1 to 32 days) in the RFA group, 13.4 days 
(range, 7 to 42 days) in the resection group and 15.0 days 
(range, 8 to 66 days) in the combination group. There was RFA and resection for colorectal liver meta
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Table 3. Clinicopathological features of patient with solitary CRLM
equal to or greater than 3 cm
Variable
RFA
(n = 14)
Resection
(n = 56)
P-value
Age 65.1 ± 8.9 58.9 ± 9.7 0.031
Sex
Male 12 (85.7) 32 (57.1) 0.043
Female 2 (14.3) 24 (42.9)
Synchronicity
Synchronous metastasis 1 (7.1) 34 (60.7) ＜0.001
Metachronous metastasis 13 (92.9) 22 (39.3)
Tumor size  3.6 ± 0.5  4.8 ± 2.2 0.058
Chemotherapy after treatment
No 0 (0) 6 (10.7) 0.248
Yes 14 (100) 50 (89.3)
Values are presented as mean ± SD or number (%).
CRLM, colorectal liver metastasis; RFA, radiofrequency ablation.
Table 4. Cox proportional hazard regression analysis of factors associated with overall survival after treatment of liver metastasis 
Variable
Univariate analysis  Multivariate analysis
a)
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-vlaue
Age 1.01 1.00-1.03 0.001 1.02 1.01-1.03 0.002
Sex
Male 1
Female 1.25 0.98-1.59 0.075
Type of treatment
Resection 1
RFA 1.20 0.91-1.56 0.191
Resection ＋  RFA 1.52 0.86-2.68 0.149
No. of liver metastasis
Single 1
Multiple 1.69 1.33-2.14 ＜0.001 1.74 1.37-2.21 ＜0.001
Maximum tumor size
＜3 cm 1
≥3 cm 1.22 0.94-1.57 0.128
Synchronicity
Synchronous metastasis 1
Metachronous metastasis 1.05 0.82-1.33 0.714
Location of liver metastasis
Unilobar 1
Bilobar 1.21 0.91-1.61 0.196
Chemotherapy after treatment
Yes 1
No 1.75 1.22-2.51 0.002 1.77 1.23-2.54 0.002
Mean follow-up period: 41.2 months (range, 2.5 to 151.6 months).
CI, confidence interval; RFA, radiofrequency ablation.
a)Variable selection: backward elimination.
Table 2. Clinicopathological features of patient with solitary CRLM
less than 3 cm
Variable
RFA
(n = 99)
Resection
(n = 127)
P-value
Age 59.8 ± 11.4 56.8 ± 11.7 0.054
Sex
Male 65 (65.7) 81 (63.8) 0.781
Female 34 (34.3) 46 (36.2)
Synchronicity
Synchronous metastasis 9 (9.1) 104 (81.9) ＜0.001
Metachronous metastasis 90 (90.9) 23 (18.1)
Tumor size  1.7 ± 0.6  1.4 ± 0.7 0.003
Chemotherapy after treatment
No 9 (9.1) 13 (10.2) 0.825
Yes 90 (90.9) 114 (89.8)
Values are presented as mean ± SD or number (%).
CRLM, colorectal liver metastasis; RFA, radiofrequency ablation.
no treatment-related mortality in each group. The mor-
bidity rates were significantly lower in the RFA group 
(RFA group vs. resection group, 6.2% vs. 21.2%; P ＜ 
0.001). The clinical features of patients with solitary 
CRLM ＜  3 cm are in Table 2 and solitary CRLM ≥  3 cm in 
Table 3. Kyung Ho Kim, et al.
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Table 5. Cox proportional hazard regression analysis of factors associated with disease-free survival after treatment of liver metastasis
Variable
Univariate analysis  Multivariate analysis
a)
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age 1.01 1.00-1.02 0.042
Sex
Male 1
Female 1.20 0.97-1.48 0.100
Type of treatment
Resection 1
RFA 1.37 1.10-1.72 0.005 1.40 1.12-1.75 0.004
Resection ＋  RFA 1.30 0.81-2.08 0.280 0.87 0.54-1.42 0.586
No. of liver metastasis
Single 1
Multiple 1.77 1.44-2.19 ＜0.001 1.85 1.48-2.30 ＜0.001
Maximum tumor size
＜3 cm 1
≥3 cm 1.02 0.81-1.29 0.856
Synchronicity
Synchronous metastasis 1
Metachronous metastasis 1.21 0.98-1.49 0.071
Location of liver metastasis
Unilobar 1
Bilobar 1.46 1.15-1.86 0.002
Chemotherapy after treatment
Yes 1
No 1.39 0.98-1.99 0.067
Mean follow-up period: 21.6 months (range, 0.1 to 151.6 months).
CI, confidence interval; RFA, radiofrequency ablation.
a)Variable selection: backward elimination.
Factors associated with OS and DFS
Univariate and multivariate analysis using Cox propor-
tional hazard analysis revealed several factors associated 
with OS after treatment of liver metastasis (Table 4). OS 
correlated with age (P = 0.002), number of liver metastases 
(P ＜  0.001) and use of chemotherapy (P = 0.002). Factors 
associated with DFS after treatment of liver metastasis 
were also analyzed (Table 5). DFS was significantly related 
to type of treatment (RFA, P = 0.004) and number of liver 
metastases (P ＜  0.001).
Outcome for patients according to patterns of liv-
er metastases 
Of the 482 patients, 296 (61.4%) had solitary liver 
metastasis. In the 226 patients with a single metastatic tu-
mor ＜3 cm (99 patients in the RFA group, 127 patients in 
the resection group), OS and DFS rates did not differ be-
tween patients who underwent RFA and resection (P = 0.96 
and 0.98, respectively). Specifically, 5-year OS and DFS 
rates were 51.1% and 33.6%, respectively, in the RFA group 
and 51.2% and 31.6%, respectively, in the resection group 
(Fig. 2). Among the 70 patients with solitary metastatic tu-
mor ≥3 cm (14 patients in the RFA group and 56 patients 
in the resection group), DFS rates were significantly lower 
in the RFA group (RFA group, 23.1%; resection group, 
36.6%; P = 0.01) (Fig. 3).
OS and DFS rates of the 186 patients with multiple liver 
metastases are shown in Fig. 4 (RFA, 64 patients; resection, 
95 patients; combination therapy, 27 patients). There were 
no statistically significant differences in OS rates among 
the groups (P = 0.330). Five-year OS was 14.3% in the RFA 
group, 34.6% in the resection group, and 22.9% in the com-
bination therapy group. However, DFS in the RFA group 
was significantly lower than the other groups (P = 0.037). 
The 5-year DFS rate was 6.4% in the RFA group, 16.2% in 
the resection group, and 18.4% in the combination therapy RFA and resection for colorectal liver meta
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Fig. 2. Survival of patients with solitary colorectal liver metastasis less than 3 cm treated by radiofrequency ablation (RFA) and resection. (A)
Overall survival (P = 0.962). (B) Disease-free survival (P = 0.980).
Fig. 4. Survival of patients with multiple colorectal liver metastasis treated by radiofrequency ablation (RFA), resection and combination 
therapy. (A) Overall survival (P = 0.330). (B) Disease-free survival (P = 0.037).
Fig. 3. Survival of patients with solitary colorectal liver metastasis equal to or greater than 3 cm treated by radiofrequency ablation (RFA) and
resection. (A) Overall survival (P = 0.152). (B) Disease-free survival (P = 0.015).Kyung Ho Kim, et al.
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group. 
Of the 224 patients with metachronous liver metastases, 
148 had solitary liver metastasis (RFA group, 103 patients; 
resection group, 45 patients). The 5-year OS rate was 47.6% 
in the RFA group and 56.0% in the resection group (P = 
0.308). There was no statistical difference in 5-year DFS be-
tween the RFA and the resection groups (32.2% vs. 34.0%, 
P = 0.164). A trend in OS and DFS rates was observed, but 
the difference was not statistically significant.
DISCUSSION
RFA produces coagulation necrosis using a high-fre-
quency alternating current delivered through an electrode 
placed in the center of the tumor [8]. RFA treatment often 
results in local tissue temperatures that approach or ex-
ceed 100
oC, inducing parenchyma and tumor cell death. 
Ultimately, the local microvasculature is destroyed as a re-
sult of thrombosis. The use of RFA is generally not recom-
mended for tumors larger than 5 to 6 cm because of techni-
cal limitations and the inability to achieve complete ne-
crosis [15]. The purpose of the current study was to com-
pare RFA with hepatic resection for the treatment of 
CRLM. Mulier et al. [4] recently advocated a randomized 
clinical trial comparing RFA and resection for resectable 
CRLM. At present, the use of RFA as an alternative treat-
ment for patients with solitary CRLM smaller than 3 cm is 
controversial. Here, we showed that outcomes associated 
with RFA were not inferior to hepatic resection in the treat-
ment of single CRLM of less than 3 cm. However, DFS 
rates after RFA were lower than surgical resection for sin-
gle CRLM ≥3 cm. These findings suggest that RFA may 
have a valuable place in the treatment of solitary CRLM of 
less than 3 cm. 
RFA has been shown to be much less invasive than hep-
atic resection, with a lower complication rate and shorter 
hospital stays [3,16-18]. Our results were consistent with 
these studies. Results from a large multicenter study dem-
onstrated that RFA is a relatively safe procedure for treat-
ing focal liver tumors, with a very low mortality rate of 
0.2% and a major complication rate of 2.2% [6]. Although 
RFA has been investigated as an alternative to surgery in 
terms of safety and feasibility, the comparative effective-
ness of RFA and other treatment modalities has yet to be 
clearly demonstrated. RFA technology continues to im-
prove, as does the skill and experience of physicians, both 
of which improve the potential of RFA as a treatment op-
tion for patients with CRLM. Results reported by Oshowo 
et al. [16] demonstrated that survival after RFA and re-
section of solitary CRLM is comparable, suggesting that 
RFA is an effective alternative treatment to conventional 
surgery. A separate but related study reported that ex-
cellent local control can be achieved with RFA for small 
liver metastasis of less than 3 cm. Local recurrence rates 
reached 8.8% overall and 1.6% for CRLM smaller than 3 
cm in diameter [19]. In patients with solitary CRLM of less 
than 3 cm, reported 5-year survival rates, including overall 
and local recurrence free survival rates, were similar be-
tween RFA and surgical resection, providing further sup-
port for RFA as an alternative treatment in patients with 
solitary CRLM smaller than 3 cm who are not suitable can-
didates for hepatic resection [20]. The results of the present 
study are consistent with these earlier studies as well as 
previous work by our group showing that RFA is a viable 
alternative treatment for solitary CRLM smaller than 3 cm 
[11]. On the other hand, several studies have shown that 
RFA is associated with higher local recurrence and shorter 
time to progression, and that there is no difference in OS 
compared to hepatic resection for CRLM [10,21]. These re-
sults are in line with the current finding that there was no 
statistically significant difference in OS between RFA and 
resection. 
RFA and resection were equivalent in terms of survival 
outcome in patients with solitary liver metastasis of less 
than 3 cm. Several studies support hepatic resection as the 
preferred treatment for CRLM, even in patients with soli-
tary tumors of less than 3 cm [3,11,22,23]. It has also been 
reported that survival following RFA for patients with un-
resectable tumors is only slightly superior to nonsurgical 
treatment [24]. In the current study, the survival rate of the 
hepatic resection group was higher than the RFA group in 
patients with solitary CRLM ≥3 cm. For patients with 
solitary CRLM smaller than 3 cm, our results suggest that 
RFA is equivalent to hepatic resection. These findings ap-
pear to contradict the results of earlier studies, including RFA and resection for colorectal liver meta
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previous work by our group looking at a smaller number 
of patients [11]. However, these discrepancies may be due 
to improvements in the technical accuracy and perform-
ance of RFA in accordance with learning curve. 
The results of a prospective randomized trial compar-
ing percutaneous local ablative therapy and partial hep-
atectomy for small hepatocellular carcinoma (HCC) were 
recently reported. Percutaneous local ablative therapy 
was as effective as surgical resection for the treatment of 
solitary and small HCC [25]. CRLM is metastatic, whereas 
HCC is a primary malignancy. However, treatment mo-
dalities are identical in small solitary tumors. The results 
of the present study indicate that RFA is a viable treatment 
alternative in patients with small solitary CRLM with poor 
medical conditions or for whom surgical resection would 
be difficult, and support moving forward with a pro-
spective randomized clinical trial comparing RFA and 
hepatic resection for solitary CRLM of less than 3 cm. In 
patients with multiple lesions, there were no significant 
differences in survival rates among the RFA, resection, 
and combination therapy groups. A trend towards slightly 
superior outcomes in the resection group was observed, 
but this was not statistically significant. These results are 
in agreement with previous reports that using RFA in ad-
dition to resection is beneficial in patients with multiple 
liver metastases because of the ability to extend the limits 
of resection [26,27].
Multivariate analysis identified the number of liver 
metastases and treatment with chemotherapy as risk fac-
tors for OS and the number of liver metastases and type of 
treatment as risk factors for DFS. These results suggest 
that systemic treatment may be more important for OS 
[28], and that local controls might be more important for 
DFS. The synchronicity of liver metastasis may also be an 
important factor in deciding whether to perform RFA or 
resection. In patients with metachronous CRLM, there is a 
tendency to avoid operation if possible because of 
invasiveness. Likewise, risk of damage to the diaphragm, 
adjacent stomach or colon would be factors against the use 
of RFA. For patients with solitary metachronous CRLM 
who want to avoid hepatic resection, RFA appears to be an 
attractive alternative. RFA technology continues to im-
prove, and it may soon be possible to achieve precise tar-
geting of tumors and larger ablation zones with a single 
electrode position [29]. Thus, RFA has the potential to im-
prove survival rates and reduce complications in selected 
patients with CRLM who are not suitable for or refuse hep-
atic resection because of comorbidities. The limitation of 
the present study was that this report was based on not a 
randomized controlled study, but a retrospective study.
In conclusion, the present study suggests that RFA may 
be a safe alternative tool for the treatment of solitary 
CRLM less than 3 cm, with outcomes equivalent to those 
achieved with hepatic resection. A prospectively con-
trolled study of RFA and resection for patients with single 
small metastasis would help to determine the most effi-
cient treatment modalities for CRLM.
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